1NH (450 mg X 300 mg) in some case under DPCO, 1987. Ceiling prices for dif. ferent pack sizes of fnis combination formulation are also being notified. Government have not received any leports of nonavailability of formulations referred to in the question.

Prices of different salts of Betamethasone

3307. SHRI DHARANIDHAR BASUMATARI: Will the Ministe, of INDUSTRY be pleased to state:

(a) whai are the different salt$_s$ of Beta methasone which were the subject matter of litigation *om* Betamethasone itself in Delhi H'gb Court and what was the p eduction of each from the date of ion to the date of promulgation of Drugs Price Control Order, 1987;

what wer$_e$ the prices of formulations charged by the company based on these drugs and thos$_e$ wh'ch were approved by Government alon: with production of each formulation yearwise;

(c) whether this Ministry made any recovery, if so. on what rate the calculation w;u made in respect of each bulk drug and formulation; and

(d) what is the present price at which each formulation is being sold and when was the price of each fixed?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) The different salts of Betamethasone involved in the Delhi High Court case are:

1. Betamethasone Alcohol
2. Betamethasone 17-Valerate
3. Betamethasone Di-Sodium Phosphate.

The production of Betamethasone during the year 1982 83 to 198'5-6 is given be'ow:

Year	Production (Kg.) M/s. Glindia ltd.
1 ')82-83 .	583.00
1983-84 .	613.88
1984-85 .	712.64
1985-R6 .	735.19

(b) and (d) The details asked lor are quite voluminous. The time and efforts required for collection of these details will ¡ not be commensurate with the results likely to be achieved.

(c) No, Sir.

Assessment of DPEA against drug companies

3308. SHRI DHARANIDHAR BASUMATARI: Will the Minister of INDUSTRY be pleased to re'fer to the answer to Unstarred Question 641 given in the ' Rajya Sab'.ia on the 2nd May. 1988 and

(a) by when the amounts due upto 31st December, 1983 would be finally assessed a;Minst the drug companies;

(b) whether it is a fact that a number of irregularities have been committed by the committee in assessing the amount;

i.ci by when the final findings of the committee would be laid ^{on} the Table of the House; and

(d) what are the details based on which tentative amounts have been assessed?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) The special team has already finalised in respect of 6 companies.

(b) No Sir.

(c) The findings of the Committee are not required to be laid on the Table otf the House. I

Id) The tentative amounts have been assessed based on the prices charged by the companies and the prices fixed by the Government.

Prices of Merliidilazine range formulations

3309. SHRI HARI SINGH:
DR. (SHRIMATI) NAJMA HHPTULTA:

Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 668 given in the Rajya Sabha °n the 2nd May, 1988 and state:

(a) what are. the names of the major formulators of Methidilazine, Nandrolone

Detonate, Hydroxyprogesterone its salts Sovental Lactate and Tolnafatc and wnat was the price of their iformulations under DPCO, 1979 and the present price under DPCO, 1987;

(b) whether the licenced capacity of Glaxo for Methidilazine is 8 tonnes per annum and not 180 tonnes per annum;

(e> w'hat are the imports of these drugs during the last three year, yearwise and their CIF import prices;

(d) what are their sales turn over as per ORG;

(e) whether any company is allowed to manufacture any of these drugs; and

(f) if so, the names of the Companies, licensed capacity Cf each and stage of manufacture alongwith the production of each during the last three years, yearwise of each producer?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) *The* required details to the extent available are given in the Statement-I.

(b) The licence^ capacity of M]s. Glindia for Methidilazine is 180kg per annum.

(c) The required details to t'he extent available are givan in the Statement-I I.

(d) Sales turnover is not Monitored.

(e) and (f) The required details to the extent available are given in the Statement-Ill.

Statement I

Name of the Company Name me of the formulation]	Pack size	Earlier price Rs. Ps.	Revised price Rs. Ps.	% age changed
1. M/s. Giindia Ltd.				
i. Dilosyn Syrup..... (Methdilazine)	120 m.	6-04	10.44	+72.8
ii. Dioloxyn Expectorant . . . . (Methdilazine	Do	5.03	9.53	+ 89.5
iii. -do-	450 ml.	13.61	23.0.	469 0
2. Mi's. German Remedies				
i. Prolucon Depot 500 mg. Amps. . (Hydroxy Progesterone)	5x2 ml.	175-00 (as claimed by the Company)	187.50	-1-7.14

Statement-II *(Rs. in lakhs)*

Sl. No.	Name of the drug	Unit	1984-85 qty.	1984-85 CIF value Rs.	1985-86 Qty.	1985-86 CIF value Rs.	1986-87 Qty I	1986-87 CIF value Rs.
1.	Hydroxy Progesterone .	Kg.	10	0.15	3	018	13	0-92
2.	Tolnafate .	Kg.	632	87.26	595	59-57	918	122.73
3.	Nandrolone Deconate .	Kgs.	3	0.27	10	0-97	14.5	1-75

Statement III

Nam* of drug/company	A/c. Unit	Capacity
MethUHIaztoe	Kg*.	180 ,
		1 80
	Kg*.	
Boehrroger-Knoll Ltd.		520.05
	Kg«.	
		100
2 Htckin A Colman		1000
		3000

Price increase of various packs of formlatiom

3310. SHRI HARI SINGH:

DR. (SHRIMATI) NAJMA HEPTULLA:

Will the Minister o'f INDUSTRY be pleased to refe- to the answer to Unstarred Question 683 given in the Rajya Sabha on 2nd May, 1988 and state:

(a) what were the prices of various packs of Dilo.iyn, Equagesic, Voveren, Pregnidoxin, Codein Linctug under DPCO 1979 and when were they approved:

(b) what are the present prices of these *T*roducts and what is the percentage increas*;

(c) what is the sales turnover of each as pet the latest ORG;

(d) what are the names of the other producers having identical products; and

(e) the names of the products which »[r]» under pnce decontrol?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) and (b) The required details to the extent available are given in the Statement. *{See* below)

(c) and (d) Sale turnover is not monitored.

(e) As per the provisions of DPCO, 1987 and guidelines issued thereunder among referred formulations only eqosgesic Tablets are under price control.

Statement

S.No.	Name of the Co./Name of the formulation	Pack size	Earlier Price	Revised Price	%ag* changnd
1	*Glmda*				
	(i) Dilosyn Expectorant	450 ml	27-74	23-00*	- 17.1
		120 ml	5.0J	9.S3	89.5
		120 ml	6.04	10.44	72.8

♦reduced with Govt, intervention.